Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,569,980
  • Shares Outstanding, K 258,788
  • Annual Sales, $ 182,240 K
  • Annual Income, $ -356,390 K
  • 60-Month Beta 1.18
  • Price/Sales 19.60
  • Price/Cash Flow N/A
  • Price/Book 9.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.21
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.27
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.77 +7.98%
on 09/11/20
14.95 -7.73%
on 08/31/20
-0.82 (-5.61%)
since 08/25/20
3-Month
12.77 +7.98%
on 09/11/20
16.13 -14.48%
on 07/13/20
-1.89 (-12.08%)
since 06/25/20
52-Week
6.25 +120.72%
on 03/16/20
16.13 -14.48%
on 07/13/20
+5.11 (+58.84%)
since 09/25/19

Most Recent Stories

More News
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy

Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines...

FOLD : 13.80 (-0.04%)
Amicus Therapeutics (FOLD) Down 7.5% Since Last Earnings Report: Can It Rebound?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOLD : 13.80 (-0.04%)
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020

Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:...

FOLD : 13.80 (-0.04%)
Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

EBS : 101.63 (+2.54%)
ALIM : 5.05 (unch)
FOLD : 13.80 (-0.04%)
ACIU : 4.78 (-1.34%)
Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

FOLD : 13.80 (-0.04%)
Amicus Therapeutics: 2Q Earnings Snapshot

CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Monday reported a loss of $52.5 million in its second quarter.

FOLD : 13.80 (-0.04%)
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of

FOLD : 13.80 (-0.04%)
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

NVAX : 113.56 (+10.86%)
HALO : 26.06 (+1.24%)
FOLD : 13.80 (-0.04%)
ICPT : 40.42 (+1.66%)
RETA : 93.83 (-8.67%)
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August...

FOLD : 13.80 (-0.04%)
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOLD : 13.80 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade FOLD with:

Business Summary

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in...

See More

Key Turning Points

2nd Resistance Point 14.15
1st Resistance Point 13.97
Last Price 13.80
1st Support Level 13.54
2nd Support Level 13.29

See More

52-Week High 16.13
Last Price 13.80
Fibonacci 61.8% 12.36
Fibonacci 50% 11.19
Fibonacci 38.2% 10.02
52-Week Low 6.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar